Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
These medications are not appropriate for everyone
Tirzepatide (dual GIP/GLP-1 agonist, not yet formally approved for obesity in the EU): in the SURMOUNT-1 study, resulted in an average weight loss of up to 22.5% at 72 weeks with the 15 mg weekly dose, approaching the effectiveness observed with some bariatric procedures
Amycretin is their next-generation one designed to potentially deliver more weight loss by targeting an additional receptor system that semaglutide doesnt touch
Quick Answer: Leg cramps are not listed as an official side effect of semaglutide in FDA labeling, but may occur indirectly through dehydration, electrolyte imbalances, or nutritional changes associated with treatment
Osteometabolism: Metabolic alterations in bone pathologies
